Brief: TC BioPharm Receives MHRA Approval For 18-Month Extrapolated Shelf-Life Of Allogeneic Cell Therapy Product, Omnimmune
13/09/2022 15:47
Sept 13 (Reuters) - TC BioPharm Ltd T0Uy.F :
* TC BIOPHARM RECEIVES MHRA APPROVAL FOR 18-MONTH
EXTRAPOLATED
SHELF-LIFE OF ALLOGENEIC CELL THERAPY PRODUCT, OMNIMMUNE®
Source text for Eikon: ID:nPncd22T1a
Further company coverage: T0Uy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange